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Abstract
Background: Bone morphogenetic proteins (BMPs) contribute to many different aspects of development including
mesoderm formation, heart development, neurogenesis, skeletal development, and axis formation. They have
previously been recognized only as secreted growth factors, but the present study detected Bmp2, Bmp4, and
Gdf5/CDMP1 in the nuclei of cultured cells using immunocytochemistry and immunoblotting of nuclear extracts.
Results: In all three proteins, a bipartite nuclear localization signal (NLS) was found to overlap the site at which the
proproteins are cleaved to release the mature growth factors from the propeptides. Mutational analyses indicated
that the nuclear variants of these three proteins are produced by initiating translation from downstream alternative
start codons. The resulting proteins lack N-terminal signal peptides and are therefore translated in the cytoplasm
rather than the endoplasmic reticulum, thus avoiding proteolytic processing in the secretory pathway. Instead, the
uncleaved proteins (designated nBmp2, nBmp4, and nGdf5) containing the intact NLSs are translocated to the
nucleus. Immunostaining of endogenous nBmp2 in cultured cells demonstrated that the amount of nBmp2 as well
as its nuclear/cytoplasmic distribution differs between cells that are in M-phase versus other phases of the cell
cycle.
Conclusions: The observation that nBmp2 localization varies throughout the cell cycle, as well as the conservation
of a nuclear localization mechanism among three different BMP family members, suggests that these novel nuclear
variants of BMP family proteins play an important functional role in the cell.
Background
Bone morphogenetic proteins (BMPs) were first identi-
fied nearly 20 years ago as components of a protein
extract derived from bone that could direct cartilage
and bone formation [1,2]. The BMPs have since been
shown to play roles in multiple other developmental
pathways [3,4]. For example, Bmp2 provides positional
information during axis formation and limb patterning
[5,6]. It is expressed in interdigital mesenchyme where
apoptosis is occurring, and it induces apoptosis in
human myeloma cells [7,8]. In contrast, Bmp2 prevents
apoptosis in a chondrocytic cell line and in breast can-
cer cells [9,10]. In the embryonic lethal Bmp2 null
mouse, amnion/chorion development is compromised
and the heart is malformed [11,12]. Bmp2 is required
for neural crest cell migration, and it promotes neuronal
differentiation in neural crest derivatives [12,13]. Bmp2
is also required for embryonic vasculogenesis and pro-
motes tumor angiogenesis [14,15].
BMPs are members of the transforming growth factor
b (TGFb) superfamily. The BMP subfamily, which
includes over twenty members, constitutes the largest
subfamily in the TGFb superfamily [16]. In addition to
BMPs, the subfamily includes mammalian growth and
differentiation factors (GDFs), decapentaplegic, 60A and
screw in Drosophila,a n dDaf-7 in Caenorhabditis ele-
gans [16]. Like other members of the TGFb superfamily,
BMPs are synthesized as preproproteins and translation
is directed to the rough endoplasmic reticulum (ER) by
N-terminal signal peptides. While in the secretory path-
way, a BMP proprotein is cleaved on the C-terminal
side of the proprotein convertase recognition sequence,
-R-X-X-R-, to release the C-terminal peptide [17,18].
The C-terminal peptide homodimerizes by disulfide
bonding to form the mature secreted growth factor
[2,8,19]. Once secreted from the cell, the active BMP
dimers signal by binding to heterotetrameric serine/
threonine kinase receptor complexes that transduce
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mitogen-activated protein kinase (MAPK) pathway
[20-23].
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secreted growth factors. We present evidence herein,
however, for the existence of nuclear variants of Bmp2,
Bmp4, and Gdf5/CDMP1. We have detected the nuclear
variant of Bmp2 (nBmp2) in a variety of different cell
types, and we demonstrate that nuclear localization of
nBmp2 is directed by a bipartite NLS that overlaps the
site of proteolytic cleavage. nBmp2 is translated from an
alternative start codon that is located downstream of the
ER signal peptide. Without the signal peptide, transla-
tion occurs in the cytoplasm and the proprotein avoids
the secretory pathway and the proprotein convertases
located therein. The bipartite NLS is therefore left intact
and directs localization to the nucleus. Examination of
other BMP family members revealed that the proteins
Bmp4 and Gdf5/CDMP1 are also detectable in the
nuclei of cultured cells. Like Bmp2, both contain NLSs
that overlap the sites of proprotein processing, and both
produce nuclear variants from downstream alternative
start codons. The existence of nuclear variants of at
least three different BMP family members suggests the
conservation of a functional role for these proteins in
the nucleus, representing a novel mechanism of BMP
function.
Results
Immunostaining reveals nuclear Bmp2
Using DNA affinity chromatography followed by mass
spectrometry, we recently observed fragments of the
Bmp2 proprotein in nuclear extracts from rat chondro-
sarcoma (RCS) cells. Suspecting cytoplasmic contamina-
tion, we performed immunofluorescent staining of three
cell lines: 10T1/2 mesenchymal cells, BALB/3T3 fibro-
blasts, and RCS cells, using primary antibodies against
Bmp2 ([N-14]:sc-6895, Santa Cruz Biotechnology). Cells
were imaged using an Olympus IX81 laser confocal
microscope to allow imaging of cellular cross-sections in
order to distinguish staining that was at or immediately
outside of the nuclear envelope from staining that was
truly nuclear. All three cell lines showed true nuclear
localization of Bmp2 (Figure 1a). Antibody specificity
was confirmed using side-by-side comparison of BALB/
3T3 cells stained with antibody that was or was not pre-
absorbed with recombinant human BMP-2 (GenScript,
Piscataway, NJ) (Figure 1b). Pre-absorption inhibited
antibody staining, including nuclear staining, confirming
that the antibody used is specific for Bmp2.
Identification of the nuclear localization signal
The PSORT II program http://psort.ims.u-tokyo.ac.jp/
was used to predict potential nuclear localization signals
(NLS) in the rat Bmp2 proprotein amino acid sequence.
Three candidate NLSs were identified. The first,
PELGRKK (named NLSa), is positioned at amino acids
26-32, almost immediately following the signal peptide.
The second, PLHKREK (named NLSb), is located at
amino acids 272-278, at the C-terminus of the propep-
tide. The third, KREKRQAKHKQRKRLKS (named
NLSc), is a bipartite nuclear localization signal situated
at amino acids 275-291, which overlaps both NLSb and
the site of proteolytic cleavage (Figure 2a).
To determine whether these potential NLSs were cap-
able of directing nuclear localization, we fused each one
to the C-terminal end of green fluorescent protein
(GFP). The fusion constructs were transiently trans-
fected into RCS cells, and cells were stained with the
Figure 1 Endogenous Bmp2 is detectable in the nuclei of three
cultured cell lines. (a) Non-transfected 10T1/2 mesenchymal cells,
BALB/3T3 fibroblasts, and RCS cells were cultured on slides and
immunostained using an anti-Bmp2 antibody (green). Nuclei were
stained with TO-PRO-3 (red), and cells were examined by laser
confocal microscopy. (b) Antibody specificity was verified by
preabsorbing anti-Bmp2 antibody with recombinant human BMP-2
before immunostaining.
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nuclei. Transfected cells were examined using an Olym-
pus IX81 laser confocal microscope. Neither NLSa nor
NLSb produced nuclear localization of GFP (Figure 2b).
Rather, GFP (a 26 kDa protein) fused to the short NLSs
was distributed throughout both the cytoplasm and the
nucleus as would be expected for a protein that is small
enough (<30-40 kD) to diffuse through nuclear pores
[24,25].
Because the two short putative NLSs bracket the free
propeptide that would be released upon proteolytic clea-
vage of the Bmp2 proprotein, we investigated whether
the two NLSs might cooperate to transport the free pro-
peptide to the nucleus. We built a construct in which
the N-terminal putative NLSa was fused to the N-termi-
nus of GFP and the C-terminal putative NLSb was fused
to the C-terminus of GFP. Transient transfection of this
construct into RCS cells revealed that even together, the
two short NLSs failed to produce nuclear localization of
GFP (Figure 2b).
Finally, we fused the putative bipartite NLSc, also con-
taining NLSb (PLHKREKRQAKHKQRKRLKS), to the
C-terminus of GFP. Transient transfection of this
expression plasmid into RCS cells produced clear
nuclear localization of GFP, indicating that the predicted
bipartite NLSc is indeed functional (Figure 2b). Compar-
ison of rat Bmp2 with the amino acid sequences of
mouse, human, chicken, and frog Bmp2 showed that the
critical basic amino acids in the bipartite NLS are 100%
conserved between these species (Figure 2c).
To determine whether the bipartite NLS was functional
in the context of full-length Bmp2, we built a fusion con-
struct designed to express the entire Bmp2 proprotein,
including the signal peptide, with GFP fused to its C-ter-
minus. This wtBmp2/GFP plasmid was transiently trans-
fected into RCS cells, and results were analyzed by
cell counting using laser confocal microscopy. Of the
cells expressing GFP, 21 ± 3% showed nuclear localization
of the wtBmp2/GFP fusion protein (Figure 2d). The
remainder of the GFP-expressing cells showed Bmp2/GFP
either evenly distributed in the nucleus and cytoplasm, or
predominantly localized to the cytoplasm. A control plas-
mid expressing only GFP produced diffuse GFP localiza-
tion in both the cytoplasm and nucleus of all transfected
cells as previously observed by others [25], verifying that
the Bmp2 portion of the fusion protein is required for
nuclear localization (data not shown).
To confirm that the bipartite NLS was necessary for
nuclear localization of Bmp2, a targeted mutation of
five amino acids within the bipartite NLS in the Bmp2/
GFP fusion construct (KREKRQAKHKQRKRLKS
changed to AAEKRQAKHKQAAALKS) was generated
(NLSmtBmp2/GFP). When transfected into RCS cells, this
construct produced 0% nuclear localization of Bmp2/GFP,
Figure 2 Bmp2 contains a functional bipartite NLS that
overlaps the site of proteolytic processing. (a) Map of the Bmp2
preproprotein showing the signal peptide, propeptide, and mature
chain. The amino acid sequence and location of each predicted NLS
is shown, and the site of proteolytic cleavage is marked by an
arrow. (b) Four GFP/NLS fusion genes were constructed as shown
to test the ability of each predicted NLS to direct GFP to the
nucleus. These expression vectors were transfected into RCS cells,
and GFP localization (green) was visualized using laser confocal
microscopy. Nuclei were stained with TO-PRO-3 (red). Only the
bipartite NLSc directed strong nuclear localization. (c) Alignment of
Bmp2 bipartite NLSc sequences from five different species. The six
basic amino acids that characterize this sequence as a bipartite NLS
are boxed. (d) To determine whether the bipartite NLSc is
functional within Bmp2, GFP was fused to the C-terminus of the
full-length Bmp2 preproprotein (wtBmp2/GFP). In a parallel fusion
construct, the bipartite NLSc was mutated (NLSmtBmp2/GFP). These
plasmids were transfected into RCS cells, and GFP localization was
visualized using laser confocal microscopy. Nuclei were stained with
TO-PRO-3 (red).
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proteolytic cleavage was essential for nuclear localization
(p < 0.001), and that no other sequence elements could
compensate for the loss of the bipartite signal (Figure 2d).
This result implied that the nuclear version of Bmp2 is
uncleaved, as cleavage would split and thus destroy the
bipartite NLS.
The nuclear localization of the wtBmp2/GFP fusion
protein and the necessity of the NLS was further con-
firmed and quantified by transfecting wtBmp2/GFP and
NLSmtBmp2/GFP plasmids into 10T1/2 and BALB3T3
cells, staining with DAPI, and analyzing GFP localization
using an ImageStream® multispectral quantitative ima-
ging flow cytometer. The ImageStream® sorted for cells
that expressed GFP and then imaged each of these cells
individually. Representative images of cells with non-
nuclear and nuclear localization of the GFP fusion pro-
tein are shown in Figure 3a. An untransfected cell is
also shown (Figure 3a, top panel).
The percent of GFP-expressing cells in each sample
that displayed nuclear localization of the GFP fusion pro-
teins was assessed by measuring the ‘Similarity’ of the
GFP and DAPI images on a per cell basis. The Similarity
score is a log-transformed Pearson’s correlation coeffi-
cient of the pixel values of the DAPI and GFP images
[26]. If GFP is localized to the nucleus, the two images
are similar and have large positive values. Similarity GFP/
DAPI overlay histograms for wtBmp2/GFP (yellow) and
NLSmtBmp2/GFP (green) in each cell line are shown
(Figure 3b). The percentage of cells with nuclear GFP
was defined by gating the events with high similarity
scores at the points indicated by the horizontal black line
in the upper right of each histogram. BALB/3T3 and
10T1/2 cells showed 27.2% and 22.0% nuclear localiza-
tion of the wtBmp2/GFP fusion protein, respectively.
Mutation of the NLS reduced nuclear localization to
3.9% and 1.4%, demonstrating once more that the bipar-
tite NLS directs nuclear localization of Bmp2 (Figure 3b).
Preventing proprotein cleavage does not increase levels
of nBmp2
We examined the possibility that uncleaved nuclear
Bmp2 could be produced by inhibition of the proprotein
convertase responsible for its cleavage. The cleavage site
of Bmp2, R-E-K-R-
↓,i sac o n s e n s u ss i t ef o rf u r i na sw e l l
as for several related members of the proprotein conver-
tase family, and furin cleaves Bmp4, the BMP family
member most closely related to Bmp2 [27-29]. To deter-
mine whether furin can cleave Bmp2, we used an in vitro
protein cleavage assay. This showed that furin can cleave
Bmp2 (Figure 4a, lanes 2 and 3) and that cleavage can be
prevented by a1-PDX, a serine protease inhibitor (serpin)
that is highly selective in its inhibition of furin (Figure 4a,
lane 4) [30-32].
To examine whether the production of nuclear Bmp2
can be increased in vivo by inhibiting proteolytic proces-
s i n go ft h eB m p 2p r o p r o t e i nb yf u r i n ,w eu t i l i z e dt h e
a1-PDX expression plasmid a1-Portland (provided by
Dr. Gary Thomas at the Oregon Health Sciences Uni-
versity in Portland, Oregon). Cotransfection of this plas-
mid with the wtBmp2/GFP fusion plasmid into RCS
cells did not produce a statistically significant increase
in the percentage of transfected cells showing nuclear
localization (p = 0.145). Likewise, cotransfection of the
Bmp2/GFP fusion plasmid with a furin expression plas-
mid did not decrease the percentage of transfected cells
showing nuclear localization (p = 0.810) (Figure 4b).
Because it is possible that another proprotein conver-
tase besides furin is responsible for the proteolytic clea-
vage of Bmp2, we constructed a cleavage mutant of
Bmp2/GFP with a disrupted consensus cleavage site but
with the essential amino acids in the bipartite NLS intact,
designated mtBmp2/GFP (KREKRQAKHKQRKRLKS
was changed to KREKGQAKHKQRKRLKS). This mutant
cannot be proteolytically processed by any member of
the proprotein convertase family, because it lacks the
essential arginine in the fourth position of the minimal
proprotein convertase recognition sequence (R-X-K/R-R)
leaving the NLS always intact [33]. This mutation, how-
ever, also failed to alter the percentage of transfected
cells showing nuclear localization (p = 0.652), suggesting
that regulation of the proprotein convertase(s) involved
in proteolytic processing of Bmp2 is probably not the
mechanism by which the uncleaved nuclear variant of
Bmp2 is produced (Figure 4b).
nBmp2 translation is initiated from a downstream
alternative start codon
We also considered the possibility that uncleaved Bmp2
could be produced by initiating translation at a down-
stream alternative start codon, which would eliminate
the signal peptide. Such a protein would not be directed
to the ER and the secretory pathway, and would thus
avoid proteolytic processing. We examined the nucleo-
tide sequence of rat Bmp2 mRNA and found, down-
stream of the conventional ATG initiation codon, an
in-frame ATG at codon 58 that was surrounded by a
partial Kozak sequence (Figure 5a) [34]. The NetStart
1.0 Prediction program http://www.cbs.dtu.dk/services/
NetStart/ indicated that codon 58 is the second most
likely translational start site in the Bmp2 transcript with
a score of 0.724, compared to 0.848 for the conventional
initiator codon 1. The mouse, human, chicken, and frog
Bmp2 sequences were also all predicted by the NetStart
1.0 program to contain strong alternative start sites at
codons 58, 59, or 60.
To test the hypothesis that codon 58 is used as an
alternative start codon, Bmp2 was transcribed and
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35S-methionine.
When the radiolabeled protein products were separated
by SDS-PAGE, the major expected band of 42 kDa
appeared as well as a minor band of approximately 38
kDa, consistent with the predicted size of a protein
initiated at codon 58 (Figure 5b, lane 1). Mutation of
codon 58 to a non-initiator AAG codon eliminated the
38-kDa band, indicating that this protein was indeed
produced by initiating translation at codon 58
(Figure 5b, lane 2).
To determine whether codon 58 can also function as
an alternative start site in vivo, we generated Bmp2/GFP
fusion constructs containing substitution mutations in
either the conventional start codon 1 or in codon 58.
These constructs were transfected into RCS cells, and
subcellular localization was visualized by fluorescent
Figure 3 The bipartite NLS directs nuclear localization of Bmp2. BALB/3T3 and 10T1/2 cells were transfected with wtBmp2/GFP or
NLSmtBmp2/GFP, stained with DAPI (red in these images), and analyzed by ImageStream® imaging flow cytometry. (a) Representative images of
cells expressing no GFP (top panel), and of cells with low (non-nuclear localization) and high (nuclear localization) similarity scores. (b) Overlay
histograms comparing similarity scores from wtBmp2/GFP and NLSmtBmp2/GFP in BALB/3T3 and 10T1/2 cells. The percentage of cells with
nuclear GFP was defined by gating the events with high similarity scores as shown by the horizontal lines in the top right of each histogram.
Percentages of cells with nuclear GFP are given (upper right).
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construct produced nuclear localization in 21 ± 3% of
transfected cells. Mutation of the conventional start
codon to compel utilization of the downstream alterna-
tive start codon dramatically increased nuclear localiza-
tion to 91 ± 3% of transfected cells. In contrast,
mutation of the alternative start codon 58 reduced
nuclear localization to only 10 ± 1%, indicating that
codon 58 is utilized to produce the nuclear variant of
Bmp2 (nBmp2) in vivo (Figure 5c).
To verify that nBmp2 is an uncleaved variant contain-
ing part of the propeptide and the bipartite NLS, two
copies of a hemaglutinin (HA) tag were inserted into
the full length Bmp2 cDNA between amino acids 132
and 133 in the propeptide region (Bmp2/proHA). (Two
copies of the tag were utilized because the anti-HA anti-
body was unable to recognize a single copy of the tag
embedded in the propeptide.) In a second construct, a
single HA tag was inserted at the C-terminus of Bmp2
(Bmp2/HA) (Figure 5d). These expression vectors con-
taining HA-tagged Bmp2 were transfected into RCS
cells, and nuclear and cytoplasmic extracts were pre-
pared. To verify that the nuclear extract was free from
cytoplasmic contamination, the nuclear and cytoplasmic
fractions were subjected to immunoblotting using a
Golgi-specific antibody (anti-Golgi 58K) (bottom two
panels, Figure 5e). Immunoblotting with an anti-HA
antibody revealed a protein of ~50 kDa in the nuclear
extract, regardless of whether the HA tag was embedded
in the propeptide or placed at the C-terminus of Bmp2,
indicating that the nuclear variant begins at a point
somewhere between the signal peptide and amino acid
133, and extends to the C-terminus of the conventional
secreted growth factor. The nuclear variant of Bmp2 is
clearly not cleaved in the middle of the bipartite NLS
(top left panel of Figure 5e).
In order to determine whether cultured cells contain
an endogenous Bmp2 protein that is localized to the
nucleus and matches the molecular weight of our ecto-
pically expressed HA-tagged Bmp2, nuclear extracts
were prepared from untransfected RCS cells and exam-
ined by immunoblotting using an anti-Bmp2 antibody.
Once again, a protein of ~50 kDa was detected in the
nuclear extract, indicating that the translation and loca-
lization of ectopically expressed nBmp2 accurately
reflects the translation and localization of endogenous
nBmp2 (top right panel, Figure 5e). (Note that the wells
used on the gel shown in the top right panel of
Figure 5e were twice as wide as those shown in the
other three panels, so the top right panel shows one
lane while the other three panels contain two lanes
each.) In addition to supporting our proposed model for
nBmp2 translation and localization, these immunoblot-
ting results also confirm the Figure 1 immunofluores-
cence results showing endogenous nBmp2 in the nuclei
of untransfected cells.
The calculated molecular weight of nBmp2 translated
from the predicted alternative start codon at amino acid
58 is 38 kDa. This is consistent with the size of the
Bmp2 protein produced in vitro where post-translational
modifications do not occur (Figure 5b). Bmp2, however,
is post-translationally modified in vivo.T h i sc a u s e st h e
full-length preproprotein, which has a predicted molecu-
lar weight of 42 kDa, to migrate at about 66 kDa on
Figure 4 Inhibition of Bmp2 proprotein processing does not
increase nuclear localization. (a) In vitro synthesis of radiolabeled
Bmp2 preproprotein produced a 43 kDa protein (lane 1, large
arrow). Incubation of this protein with recombinant furin for 1 or 3
hours generated a new protein band at 31 kDa, the predicted size
of the free Bmp2 propeptide following proteolytic cleavage (lanes
2 and 3, small arrow). Preincubation of the furin with a1PDX, a
serine protease inhibitor that blocks furin activity, prevented the
formation of this band (lane 4). (b) Furin and a1PDX expression
plasmids were each cotransfected with the wtBmp2/GFP fusion
plasmid into RCS cells. Increasing furin expression did not
significantly decrease nuclear localization of Bmp2/GFP, nor did
inhibiting furin activity with a1PDX significantly increase nuclear
localization. Mutation of the Bmp2 cleavage site to make it
unrecognizable by furin or any related proprotein convertase
(mtBmp2/GFP) also failed to significantly increase nuclear
localization of Bmp2/GFP.
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tional modifications also account for the discrepancy
between the calculated size of nBmp2 (38 kDa) and its
observed electrophoretic mobility (50 kDa).
Nuclear localization of nBmp2 varies throughout the cell
cycle
The observation that only about 20% of the cells expres-
sing wtBmp2/GFP display nuclear localization of GFP at
any given moment suggested that the nuclear localization
of nBmp2 may vary throughout the cell cycle. To address
this question, we serum-starved 10T1/2 cells for 24 hours
and then returned serum to the culture medium so many
cells would enter mitosis simultaneously. At various time
points after serum replacement, cells were stained by
immunofluorescence using primary antibodies against
endogenous Bmp2 ([N-14]:sc-6895, Santa Cruz Biotech-
nology) and imaged using an Olympus IX81 laser confocal
microscope. The four-hour time point yielded many mito-
tic cells, including cells in prophase, metaphase, anaphase,
telophase, and cytokinesis. Cells that were not undergoing
mitosis showed predominantly nuclear localization of
Bmp2/GFP (Figure 6f). In contrast, cells in late prophase,
when nuclear envelope breakdown occurs, showed intense
Bmp2/GFP staining throughout the entire cell except in
the location of chromosome condensation (Figure 6a).
Cells in metaphase, anaphase, and telophase also showed
more intense Bmp2/GFP staining than surrounding cells,
but staining was excluded from the site where condensed
chromosomes were located (Figure 6b-d). In cells
Figure 5 Translation of Bmp2 from an alternative start codon downstream of the signal peptide produces the uncleaved nuclear
variant of Bmp2. (a) The N-terminus of the rat Bmp2 protein with corresponding DNA sequence is shown. The conventional (codon 1) and
predicted alternative (codon 58) start codons are marked (arrowheads), and the signal peptide is shown in italics. (b) In vitro synthesis of Bmp2
produced the expected 42 kDa protein and some lower molecular weight proteins (lane 1). Mutation of codon 58 eliminated one of the smaller
proteins, indicating that it was initiated at codon 58 (arrow). (c) Bmp2/GFP fusion constructs containing substitutions in either the conventional
start codon 1 (ATG1 mtBmp2/GFP) or the alternative start codon 58 (ATG58 mtBmp2/GFP), were transfected into cells, and the percentage of
transfected cells showing nuclear localization was quantified. (d) HA tags were inserted into the propeptide or fused to the C-terminus of Bmp2
as shown. (e) The HA tagged expression vectors were transfected into RCS cells, and nuclear extracts were analyzed by western blotting. Both
vectors produced an HA-tagged nuclear protein of ~50 kDa (top left panel). When nuclear extracts from non-transfected RCS cells were analyzed
by western blotting using an anti-Bmp2 antibody, a ~50 kDa endogenous nuclear protein was labeled (top right panel–note that this panel
contains only one wide lane). Nuclear (N) and cytoplasmic (C) extracts were probed using a Golgi-specific antibody to verify that the nuclear
extracts were not contaminated with cytoplasmic proteins (bottom panels).
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densing and nuclear membranes reforming, Bmp2/GFP
staining was cytoplasmic (Figure 6e), suggesting that
nuclear translocation of nBmp2 is necessary after each cell
division to re-establish the pattern of nuclear localization
observed in non-mitotic cells (Figure 6f).
nBmp4 and nGdf5 are produced by similar mechanisms
To determine whether the existence of nuclear variants
might be conserved among other BMP family members,
we utilized the PSORT II program http://psort.ims.
u-tokyo.ac.jp/ to search their amino acid sequences for
putative NLSs. Two proteins, Bmp4 and Gdf5, were
selected for further study because each contained a pre-
dicted bipartite NLS overlapping the site of proprotein
processing, as in Bmp2 (Figure 7a and 7d). When fused
to GFP, both of these predicted NLSs were found cap-
able of directing translocation of GFP to the nucleus in
RCS cells (data not shown). Immunofluorescent staining
was performed on cultured 10T1/2, BALB/3T3, and
RCS cells to see if endogenous Bmp4 and Gdf5 could be
detected in the nuclei. Using primary antibodies against
Bmp4 (JM-5674-100, MBL International), we found
that nuclear Bmp4 was detectable in all three cell lines
(Figure 7b). Using primary antibodies against Gdf5
((N-17):sc-6901, Santa Cruz Biotechnology), we found
that Gdf5 was detectable in the nuclei of 10T1/2 and
BALB/3T3 cells, but was not localized to the nucleus in
RCS cells (Figure 7e).
To determine whether the bipartite NLSs were necessary
for the nuclear localization of Bmp4 and Gdf5, GFP was
fused to the C-terminus of each full-length protein. When
transfected into RCS cells, the wtBmp4/GFP fusion con-
struct showed nuclear localization in 29 ± 6% of trans-
fected cells (Figure 7c) and the wtGDF5/GFP fusion
construct showed nuclear localization in 20 ± 3% of trans-
fected cells by manual counting on an Olympus IX81 laser
confocal microscope (Figure 7f). Targeted mutation of
the bipartite NLS in Bmp4 (RRAKRSPKHHPQRSRKK
was changed to AAAKRSPKHHPQRSAAV)m a r k e d l y
reduced nuclear localization (p < 0.001) (NLSmtBmp4/
GFP, Figure 7c). Targeted mutation of the bipartite
NLS in Gdf5 (RKRRAPLATRQQKRPSK changed to
AARRAPLATRQQAAPSK) completely eliminated nuclear
localization (p < 0.001) (NLSmutGDF5/GFP, Figure 7f),
demonstrating that the bipartite NLSs overlapping the
sites of proprotein processing are necessary for nuclear
localization of both Bmp4 and Gdf5.
Because nBmp2 is translated from a downstream alter-
native start codon, Bmp4 and Gdf5 were examined
using the NetStart 1.0 Prediction program http://www.
cbs.dtu.dk/services/NetStart/ to identify possible alterna-
tive start codons. Bmp4 contained a predicted alterna-
tive start site at codon 83 (Figure 7a). When the
conventional start site at codon 1 was mutated (ATG
changed to AAG) in the context of the Bmp4/GFP
fusion protein to force utilization of downstream alter-
native start codons (ATG1 mtBmp4/GFP), nuclear loca-
lization increased to 80% of transfected cells (p = 0.035)
(Figure 7c). Targeted mutation of codon 83 (ATG83
mtBmp4/GFP), in contrast, reduced nuclear localization
by approximately one-half to 16% (p = 0.010)
(Figure 7c), indicating that codon 83 can indeed be used
Figure 6 The intensity of staining and nuclear localization of
nBmp2 differ between M-phase and the other phases of the
cell cycle. 10T1/2 cells were cultured on slides for 24 hrs in the
absence of serum, and then serum was replaced at time zero. Cells
were immunostained using an anti-Bmp2 antibody (green) to
visualize nBmp2 in cells at different stages of the cell cycle. Nuclei
were stained with TO-PRO-3 (red), and cells were examined by laser
confocal microscopy. Panels a-e show mitotic cells imaged at the 4
hr. time point. (a) A cell in late prophase (arrow) shows more
nBmp2 staining than surrounding non-mitotic cells, with the least
intense staining in the region of chromosome condensation. A
metaphase cell is also visible in this frame. Cells in metaphase (b),
anaphase (c), and telophase (d) (arrows) show more intense Bmp2
staining than surrounding non-mitotic cells, and staining is reduced
where condensed chromosomes are located. (f) Non-mitotic cells
imaged at the 8 hr. time point show nuclear localization of nBmp2.
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Page 8 of 14as a start site for translation of the nuclear variant of
Bmp4 (nBmp4).
When the conventional start site at codon 1 in Gdf5
was mutated (ATG changed to AAG) in the context
of the GDF5/GFP fusion construct (ATG1 mtGDF5/
GFP) to force utilization of downstream alternative
start codons, nuclear localization increased to 78% of
transfected cells (p < 0.001), indicating that the nuclear
variant of Gdf5 is also translated from one or more
downstream alternative start codons (Figure 7f). Muta-
tion of a possible CTG alternative start site (CTG chan-
ged to AAG) at codon 53 did not change the percent of
transfected cells showing nuclear localization of GDG5/
GFP, suggesting that this site does not serve as an alter-
native start codon (data not shown). The first in-frame
ATG after codon 1 is found at codon 173. When
this site was mutated (ATG changed to AAG), nuclear
localization was reduced to 7% of transfected cells
Figure 7 Nuclear variants of Bmp4 and Gdf5 are also translated from downstream alternative start codons and contain NLSs that
overlap the sites of proprotein processing. (a) Map of the Bmp4 preproprotein showing the signal peptide, propeptide, and mature chain.
The amino acid sequence and location of the bipartite NLS are shown, and the alternative start codon and site of proteolytic cleavage are
marked. (b) Endogenous Bmp4 is detectable in the nuclei of three cultured cell lines. Non-transfected 10T1/2, BALB/3T3, and RCS cells were
cultured on slides and immunostained using an anti-Bmp4 antibody (green). Nuclei were stained with TO-PRO-3 (red), and cells were examined
by laser confocal microscopy. (c) Bmp4/GFP fusion constructs containing targeted mutations in the NLS, the conventional start codon 1, or the
alternative start codon 83, were transfected into RCS cells to examine the effects of these mutations on nuclear localization of Bmp4. (d) Map of
the Gdf5 preproprotein showing the signal peptide, propeptide, and mature chain. The amino acid sequence and location of the bipartite NLS
are shown, and the alternative start codon and site of proteolytic cleavage are marked. (e) Endogenous Gdf5 is detectable in the nuclei of two
of the three cultured cell lines shown. Non-transfected 10T1/2, BALB/3T3, and RCS cells were cultured on slides and immunostained using an
anti-Gdf5 antibody (green). Nuclei were stained with TO-PRO-3 (red), and cells were examined by laser confocal microscopy. (f) GDF5/GFP fusion
constructs containing targeted mutations in the NLS, the conventional start codon 1, or the alternative start codon 173, were transfected into
RCS cells to examine the effects of these mutations on nuclear localization of Gdf5.
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Page 9 of 14(p = 0.012) (Figure 7f), indicating that codon 173 can
serve as an alternative start codon for the translation of
nuclear Gdf5 (nGdf5).
Discussion
The results presented here demonstrate that translation
that begins downstream of the ER signal peptide drives
nuclear localization of Bmp2, Bmp4, and Gdf5. In each
case, elimination of the signal peptide prevents transla-
tion of the nascent polypeptide into the ER and thereby
prevents transit through the secretory pathway, which in
turn prevents contact with the Golgi-localized propro-
tein convertases that would otherwise cleave the propro-
tein and destroy its NLS. These findings indicate that
nuclear Bmp2, Bmp4, and Gdf5 proteins translated from
alternative downstream start codons cannot function in
their traditional role as ligands binding to cell surface
receptors, because they cannot enter the secretory path-
way. Likewise, processed and secreted Bmp2, Bmp4, and
Gdf5 would not be likely to enter the nucleus after
binding to cell surface receptors and being internalized,
as their NLSs are destroyed by proprotein processing.
This mechanism for producing nuclear variants of BMP
family proteins stands in contrast to several other
growth factors including EGF family members, IFNg,
FGF family members, prolactin, and growth hormone
[36,37]. In these examples, growth factors are secreted
from the cell, bind to plasma membrane receptors, and
are internalized prior to translocation of the ligand and/
or its receptor to the nucleus.
The nuclear localization of growth factor variants that
avoid the secretory pathway is not unprecedented. A
nuclear form of parathyroid hormone-related peptide
(PTHrP) can be generated by translation from an alter-
native start site downstream of the conventional initiator
ATG, producing a protein with a truncated signal pep-
tide much like nBmp2, nBmp4, and nGdf5. Loss of the
signal peptide enables PTHrP to bypass the ER and
secretory pathway, and an embedded NLS then interacts
with importin b1 to direct PTHrP to the nucleus
[38,39]. Another example of nuclear localization due to
utilization of an alternative start codon is found in the
basic fibroblast growth factor (bFGF). In one form of
this protein, nuclear localization is determined by trans-
lational initiation at an upstream alternative start site.
The utilization of an upstream CUG start codon pro-
duces a variant protein with an extended amino termi-
nus containing an NLS that directs nuclear localization
[40]. In the case of fibroblast growth factor 3 (FGF3),
translation can initiate at a CUG codon that is 87
nucleotides upstream of the first AUG in the protein-
coding frame. These 87 nucleotides code for two NLS
signals and a hydrophobic secretory signal, and the bal-
ance between nuclear localization and secretion of this
protein variant is determined by the competing signals
[41,42]. These examples demonstrated a precedent for
altering the subcellular localization of proteins by initiat-
ing translation from alternative start sites, and they
show that nuclear localization of growth factors can
occur without prior secretion of the protein from the
cell [43].
The novel location of the bipartite NLS in Bmp2,
overlapping the site of proprotein processing, initially
led us to consider a different mechanism of nuclear
localization. We examined whether inhibition of propro-
tein processing might leave the NLS intact and thus
lead to nuclear localization of Bmp2. This hypothesis
was considered because regulation of furin activity has
been shown to affect the activity of furin substrates in
other cases. For example, the pro-b-NGF protein is a
neurotropin that has opposing activities depending on
whether or not it is cleaved by furin. Cleaved b-NGF
promotes cell survival, whereas uncleaved b-NGF pro-
motes apoptosis of neurons [44]. Furin is also responsi-
ble for cleavage of the transmembrane receptor Notch.
Cleavage results in the release of the Notch intracellular
domain, which goes to the nucleus and activates genes
involved in development and differentiation [45].
Uncleaved Notch, in contrast, inhibits cell differentiation
[46]. The experiments presented here, however, do not
support a role for furin modulation in regulating the
localization of Bmp2.
Instead, this work has demonstrated that nBmp2,
nBmp4, and nGdf5 are all produced by initiating trans-
lation from a location downstream of the signal peptide.
In each protein, an alternative start codon was identi-
fied, the mutation of which reduced nuclear localization
by approximately 50%. These codons were located at
amino acid positions 58, 83, and 173 in Bmp2, Bmp4
and Gdf5, respectively. Interestingly, these different start
sites produce nuclear variants that are 336, 326, and 329
amino acids long for nBmp2, nBmp4, and nGdf5,
respectively. The differences in the lengths of the three
proproteins, therefore, are almost entirely accounted for
by differences upstream of the alternative start codons,
suggesting that selective pressure has played a role in
maintained the lengths of the nuclear variants.
The observation that mutation of the alternative start
codons reduced but did not eliminate synthesis of the
nuclear variants of each protein suggests that, at least in
ectopically expressed fusion constructs, other sites can
serve as start codons for synthesis of the nuclear var-
iants when the primary alternative start sites are elimi-
nated. Indeed, the NetStart 1.0 program predicted
several weaker alternative start codons in each propep-
tide coding region. It is not clear, however, whether
usage of any other alternative start codons ever occurs
in vivo.
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expressed the three wild type BMP/GFP fusion con-
structs showed nuclear localization of the fusion pro-
teins suggested that translational start site selection and/
or nuclear translocation might be regulated, perhaps in
association with the cell cycle. Indeed, immunofluores-
cence staining of endogenous Bmp2 in cells undergoing
mitosis demonstrated that cells entering M-phase of the
cell cycle display the most intense staining, which might
reflect increased utilization of the alternative start codon
during the G2/M phase of the cell cycle. A similar pat-
tern of subcellular localization throughout the cell cycle
has been reported for PTHrP, and it has been suggested
that this pattern “supports a role for PTHrP in cell divi-
sion” [47]. Dissolution of the nuclear envelope seemed
to allow nBmp2 to spread throughout the cell, either by
diffusion or active transport, and when the nuclear
envelope reassembled during cytokinesis, nBmp2 was no
longer preferentially localized to the nucleus. These
observations suggest that new nuclear translocation of
nBmp2 is required to re-establish nuclear localization
every time a cell completes M-phase of the cell cycle.
Additional experiments will be required to determine
whether the same nBmp2 molecules can be re-trans-
ported to the nucleus, or whether de novo protein
synthesis is required after each cell division. Likewise,
additional experiments are needed to explore whether
nBmp2 plays any role in cell division.
Conclusions
In summary, the experiments presented here have
demonstrated by immunofluorescence staining that
endogenous Bmp2 is detectable in the nuclei of three
different cultured cell lines. GFP fusion constructs
showed that the bipartite NLS overlapping the site of
proteolytic cleavage is essential for nuclear localization
of Bmp2, and that the nuclear variant of Bmp2 is pro-
duced from a downstream alternative start codon. These
results are further supported by immunoblots demon-
strating the presence of endogenous nBmp2 in nuclear
extracts and showing that the electrophoretic mobility
of endogenous nBmp2 is the same as that of ectopically
expressed, HA-tagged nBmp2. Nuclear localization of
nBmp2 was shown to vary as cells progressed through
the cell cycle, consistent with the observation that only
about 20% of transfected cells showed nuclear localiza-
tion of ectopic wtBmp2/GFP at any given time. The
Bmp2 data described here is further bolstered by the
demonstration that BMP family members Bmp4 and
Gdf5 are also detectable in the nucleus by immunocyto-
chemistry and are synthesized and localized to the
nucleus by similar means. Together, these results indi-
cate that Bmp2, Bmp4, and Gdf5 can be alternatively
translated as secreted growth factors or as nuclear
proteins.
Conservation of nuclear variants of three different
BMP family members, and conservation of the mechan-
ism by which their nuclear localization occurs, suggests
a conserved functional role for these three proteins in
the nucleus. The observation that nBmp2 localization
differs at different stages of the cell cycle also suggests a
functional role for this novel protein. Our earliest obser-
vation of nBmp2 among nuclear proteins that had been
purified by DNA affinity chromatography suggests that
nBmp2 may bind DNA, perhaps to regulate transcrip-
tion. Computational analysis, however, shows no pre-
dicted DNA-binding domain in nBmp2. Furthermore,
electrophoretic mobility shift assays have so far failed to
show direct binding of nBmp2 to DNA. It remains pos-
sible that nBmp2 interacts indirectly with DNA as part
of a protein complex, and this possibility is currently
being explored by examining the array of proteins with
which nBmp2 interacts. We have also used targeted
mutagenesis to produce a mouse in which nBmp2 can-
not be translocated to the nucleus. Analysis of this
mouse’s phenotype is currently underway and is just
beginning to yield interesting insights into the functional
role of nBmp2.
Methods
Construction of plasmids and mutagenesis
The pCMV/GFP-NLSa, pCMV/GFP-NLSb and pCMV/
GFP-NLSc constructs were generated by annealing com-
plementary oligonucleotides encoding PELGRKK,
PLHKREK and PLHKREKRQAKHKQRKRLKS respec-
tively with additional nucleotides to create NotIo rPstI
ends, allowing ligation into the appropriate site of GFP
in the pCMV/myc/ER/GFP vector. pCMV/myc/ER/GFP
was used as a control in transfection experiments, with
an inserted stop codon right after GFP.
wtBmp2 was generated by synthesizing cDNA from
mRNA extracted from RCS cells using the Qiagen One-
Step RT-PCR kit (Qiagen, Valencia, CA) with primers
including a BamHI site and a XbaI site allowing ligation
into pcDNA3.1. This plasmid was used as a template for
the production of the Bmp2/GFP fusion construct using
a GFP Fusion TOPO TA Expression Kit (Invitrogen
Corporation, Carlsbad, CA) according to the manufac-
turer’s instructions.
Bmp2/HA and Bmp2/proHA were constructed utiliz-
ing the QuikChange II Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA) following the directions of the
manufacturer. The template employed was wtBmp2 in
pcDNA3.1 with primers designed to insert an HA tag at
the C-terminus of Bmp2 or two HA tags between amino
acids 132 and 133.
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made by site-directed mutagenesis, using the Quik-
Change II Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA) according to the manufacturer’si n s t r u c t i o n s .
For the cleavage site mutant, mtBmp2/GFP, primers
were designed to introduce a glycine in place of argi-
nine-279. The ATG1 mtBmp2, ATG1 mtBmp2/GFP,
ATG58 mtBmp2, and ATG58 mtBmp2/GFP plasmids
were made in the same manner, mutating the ATG sites
to AAG. For the NLSmtBmp2/GFP, the following amino
acids were converted to alanines: lysine-275, arginine-
276, arginine-286, lysine-287, and arginine-288.
wtBmp4/GFP and wtGDF5/GFP were generated by
PCR amplification of Bmp4 from the mouse Bmp4
expression plasmid SP72/BMP4 (provided by Dr. Ronald
Koenig at the University of Michigan in Ann Arbor, MI)
and GDF5 from the human GDF5 expression vector
pCol2a1-CDMP1 (provided by Dr. Yoshihiko Yamada at
the National Institute of Dental and Craniofacial
Research, Bethesda, MD) and cloned into the GFP
Fusion TOPO TA Expression vector as detailed above.
The QuikChange II Site-Directed Mutagenesis Kit was
again used to generate the mutant constructs. For
NLSmtBmp4/GFP the following amino acids were con-
verted to alanines: arginine-288, arginine-289, arginine-
302, and lysine-303. Lysine-304 was converted to valine.
The ATG1 and ATG83 sites were mutated from ATG
to AAG. For GDF5, the NLSmtGDF5/GFP has the fol-
lowing amino acids changed to alanines: arginine-378,
arginine-379, lysine-390, and arginine-391. The ATG1
and ATG173 sites were mutated from ATGt oA AG.
All primers and the complementary oligonucleotide
strands were synthesized by Invitrogen Life Technolo-
gies. All constructs were verified by DNA sequence ana-
lysis in the BYU DNA Sequencing Center, Brigham
Young University, Provo, UT.
Cell culture and transfection
Rat chondrosarcoma (RCS) cells, 10T1/2 cells, and
BALB/3T3 cells were maintained in Dulbecco’s modified
Eagle’s medium supplemented with penicillin (50 U/ml),
streptomycin (50 μg/ml), L-glutamine (2 mM) and 10%
fetal calf serum at 37°C under 5% CO2. For transient
DNA transfections, TransIT-Jurkat Transfection Reagent
(Mirus, Madison WI) was used according to manufac-
turer’s direction.
Immunofluorescence labeling and microscopy
RCS cells that had been transfected with GFP fusion
constructs were fixed using 4% paraformaldehyde/PBS
and the nuclei were stained with TO-PRO-3 iodide
(Invitrogen Corporation, Carlsbad, CA) according to
manufacturer’s protocol.
To visualize endogenous Bmp2, Bmp4, and Gdf5, non-
transfected RCS, BALB/3T3, and 10T1/2 cells grown on
Lab-Tek II Chamber slides (ISC Bioexpress) were fixed
in 4% paraformaldehyde, permeabilized and incubated
with one of the following primary antibodies: BMP-2
(N-14: sc-6895, Santa Cruz Biotechnology), Bmp4 (JM-
5674-100, MBL International), or GDF-5 (N-17: sc-6901,
Santa Cruz Biotechnology). After washing, cells were
incubated with Alexa Fluor 488-tagged secondary anti-
bodies (Invitrogen Corporation, Carlsbad, CA), mounted
in Fluoromount-G (Southern Biotech, Birmingham, AL),
and coverslipped. For images of 10T1/2 cells at various
stages of the cell cycle, cells were serum-starved for 24
hours. Imaging was performed at different time points
after the replacement of 10% fetal calf serum. Antibody
specificity was verified by incubating the anti-Bmp2
antibody overnight at 4°C in the presence or absence of
a 10-fold molar excess of recombinant human BMP-2
(GenScript, Piscataway, NJ). This pre-absorbed primary
antibody was then used to immunostain BALB/3T3 cells
as described above.
Cells were imaged using an Olympus IX81 laser con-
focal microscope with an Olympus UPlanF1 40× 1.3 oil
objective and Fluoview version 4.3 image acquisition
software, using excitation wavelengths of 488 nm and
633 nm. All imaging was performed in the BYU Confo-
cal Microscope Lab.
ImageStream® analysis
BALB/3T3 and 10T1/2 cells were trypsinized, washed in
phosphate buffered saline (PBS), and fixed in 1% paraf-
ormadahyde in PBS for shipping. Nuclei were stained
with 4’,6-diamidino-2-phenylindole (DAPI) immediately
prior to analysis. Analysis of nuclear localization was
performed by Amnis Corporation (Seattle, WA) on an
ImageStream® multispectral quantitative imaging flow
cytometer. Normal single cells expressing GFP were dis-
tinguished from untransfected cells, debris, and multi-
cellular aggregates by gating using IDEAS software.
Images of individual GFP-expressing cells were analyzed
by measuring the ‘Similarity’ of the GFP and DAPI
images. The Similarity score is a log-transformed Pear-
son’s correlation coefficient of the pixel values of the
DAPI and GFP images. If GFP is localized to the
nucleus, the two images will be similar and have large
positive Similarity values [26].
In vitro transcription/translation and in vitro digestion
assay
Bmp2 protein was synthesized with the incorporation of
[
35S]methionine employing the TNT Coupled Wheat
Germ Extract System (Promega, Madison, WI) accord-
ing to manufacturer’s instructions using an expression
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Page 12 of 14vector containing the rat Bmp2 cDNA. Ten units of
furin (New England BioLabs, Ipswich, MA) or furin plus
2 μM a1-PDX (Affinity BioReagents, Golden, CO) were
preincubated for 30 min at room temperature. The
labeled Bmp2 proprotein was then added, and the reac-
tion was allowed to proceed for 1 hour or 3 hours
before products were separated by SDS-PAGE and
visualized by autoradiography.
Immunoblotting
Nuclear and cytoplasmic proteins were separated and
isolated using the Cellytic Nuclear Extraction Kit
(Sigma, Saint Louis, MO) according to manufacturer’s
instructions. Western blotting was performed on
extracted nuclear and cytoplasmic proteins with the fol-
lowing primary antibodies: anti-HA antibody (EQD
Bioscience Inc. San Diego, CA), anti-Bmp2 (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) or anti-Golgi 58K
(Sigma, Saint Louis, MO). This was followed by incuba-
tion with the appropriate horseradish peroxidase-conju-
gated secondary antibody.
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